Phosphorylation sites in the PDGF receptor with different specificities for binding GAP and PI3 kinase in vivo.

Phosphatidylinositol 3-kinase: structure and expression of the 110 kd catalytic subunit.

Interaction of the p85 subunit of PI 3-kinase and its N-terminal SH2 domain with a PDGF receptor phosphorylation site: structural features and analysis of conformational changes.

Phosphatidylinositol 3'-kinase is activated by association with IRS-1 during insulin stimulation.

Inhibition of SH2 domain/phosphoprotein association by a nonhydrolyzable phosphonopeptide.

Measurement of the binding of tyrosyl phosphopeptides to SH2 domains: a reappraisal.

Formation of signal transfer complexes between stem cell and platelet-derived growth factor receptors and SH2 domain proteins in vitro.

Phosphotyrosine-dependent interaction of SHC and insulin receptor substrate 1 with the NPEY motif of the insulin receptor via a novel non-SH2 domain.

Non-SH2 domains within insulin receptor substrate-1 and SHC mediate their phosphotyrosine-dependent interaction with the NPEY motif of the insulin-like growth factor I receptor.

p56Lck and p59Fyn regulate CD28 binding to phosphatidylinositol 3-kinase, growth factor receptor-bound protein GRB-2, and T cell-specific protein-tyrosine kinase ITK: implications for T-cell costimulation.

Selective CD28pYMNM mutations implicate phosphatidylinositol 3-kinase in CD86-CD28-mediated costimulation.

Interaction of p85 subunit of PI 3-kinase with insulin and IGF-1 receptors analysed by using the two-hybrid system.

Localization of the insulin-like growth factor I receptor binding sites for the SH2 domain proteins p85, Syp, and GTPase activating protein.

Interaction of the Flt-1 tyrosine kinase receptor with the p85 subunit of phosphatidylinositol 3-kinase. Mapping of a novel site involved in binding.

SH2 domains exhibit high-affinity binding to tyrosine-phosphorylated peptides yet also exhibit rapid dissociation and exchange.

A photoaffinity scan maps regions of the p85 SH2 domain involved in phosphoprotein binding.

Two signaling molecules share a phosphotyrosine-containing binding site in the platelet-derived growth factor receptor.

Growth hormone, interferon-gamma, and leukemia inhibitory factor promoted tyrosyl phosphorylation of insulin receptor substrate-1.

Src phosphorylation of the epidermal growth factor receptor at novel sites mediates receptor interaction with Src and P85 alpha.

CTLA-4 binding to the lipid kinase phosphatidylinositol 3-kinase in T cells.

1-Phosphatidylinositol 3-kinase activity is required for insulin-stimulated glucose transport but not for RAS activation in CHO cells.

T-cell antigen CD28 interacts with the lipid kinase phosphatidylinositol 3-kinase by a cytoplasmic Tyr(P)-Met-Xaa-Met motif.

Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling.

Identification of Trk binding sites for SHC and phosphatidylinositol 3'-kinase and formation of a multimeric signaling complex.

Direct activation of the phosphatidylinositol 3'-kinase by the insulin receptor.

Specific phosphopeptide binding regulates a conformational change in the PI 3-kinase SH2 domain associated with enzyme activation.

Ligand-binding properties of the two isoforms of the human insulin receptor.

Structure-activity studies of phosphorylated peptide inhibitors of the association of phosphatidylinositol 3-kinase with PDGF-beta receptor.

Interaction of the molecular weight 85K regulatory subunit of the phosphatidylinositol 3-kinase with the insulin receptor and the insulin-like growth factor-1 (IGF- I) receptor: comparative study using the yeast two-hybrid system.

Structure of a specific peptide complex of the carboxy-terminal SH2 domain from the p85 alpha subunit of phosphatidylinositol 3-kinase.

Structural and thermodynamic characterization of the interaction of the SH3 domain from Fyn with the proline-rich binding site on the p85 subunit of PI3-kinase.

Dual specificity of Src homology 2 domains for phosphotyrosine peptide ligands.

Yeast two-hybrid in vivo association of the Src kinase Lyn with the proto-oncogene product Cbl but not with the p85 subunit of PI 3-kinase.

Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site.

The phosphatidylinositol 3' kinase pathway is required for the survival signal of leukocyte tyrosine kinase.

Interaction of the cytoplasmic tail of CTLA-4 (CD152) with a clathrin-associated protein is negatively regulated by tyrosine phosphorylation.

Growth factor receptor-bound protein 2 SH2/SH3 domain binding to CD28 and its role in co-signaling.

Association of the insulin receptor with phospholipase C-gamma (PLCgamma) in 3T3-L1 adipocytes suggests a role for PLCgamma in metabolic signaling by insulin.

Determination of Gab1 (Grb2-associated binder-1) interaction with insulin receptor-signaling molecules.

Resting lymphocyte kinase (Rlk/Txk) phosphorylates the YVKM motif and regulates PI 3-kinase binding to T-cell antigen CTLA-4.

Fyn associates with Cbl and phosphorylates tyrosine 731 in Cbl, a binding site for phosphatidylinositol 3-kinase.

A fluorescent indicator for tyrosine phosphorylation-based insulin signaling pathways.

Dominance of ErbB-1 heterodimers in lung epithelial cells overexpressing ErbB-2. Both ErbB-1 and ErbB-2 contribute significantly to tumorigenicity.

Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by protein-tyrosine phosphatase 1B. Possible facilitation by the formation of a ternary complex with the Grb2 adaptor protein.

Alternative modes of binding of proteins with tandem SH2 domains.

Association of Grb2, Gads, and phospholipase C-gamma 1 with phosphorylated LAT tyrosine residues. Effect of LAT tyrosine mutations on T cell angigen receptor-mediated signaling.

GRID: a novel Grb-2-related adapter protein that interacts with the activated T cell costimulatory receptor CD28.

Identification of major tyrosine phosphorylation sites in the human insulin receptor substrate Gab-1 by insulin receptor kinase in vitro.

NMR structure of the N-SH2 of the p85 subunit of phosphoinositide 3-kinase complexed to a doubly phosphorylated peptide reveals a second phosphotyrosine binding site.

Split luciferase as an optical probe for detecting protein-protein interactions in mammalian cells based on protein splicing.

Tyr(612) and Tyr(632) in human insulin receptor substrate-1 are important for full activation of insulin-stimulated phosphatidylinositol 3-kinase activity and translocation of GLUT4 in adipose cells.

Tyrosine phosphorylation-dependent yeast two-hybrid system for the identification of the SH2 domain-binding proteins.

PLC-gamma1 enzyme activity is required for insulin-induced DNA synthesis.

Use of signal specific receptor tyrosine kinase oncoproteins reveals that pathways downstream from Grb2 or Shc are sufficient for cell transformation and metastasis.

Locating a protein-protein interaction in living cells via split Renilla luciferase complementation.

Human homolog of disc-large is required for adherens junction assembly and differentiation of human intestinal epithelial cells.

TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma.

The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex.

Insulin receptor substrate is a mediator of phosphoinositide 3-kinase activation in quiescent pancreatic cancer cells.

A quantitative protein interaction network for the ErbB receptors using protein microarrays.

NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells.

Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1.

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.

Toll-like receptor 3 associates with c-Src tyrosine kinase on endosomes to initiate antiviral signaling.

Direct binding of p85 to sst2 somatostatin receptor reveals a novel mechanism for inhibiting PI3K pathway.

Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation.

The PI3K p110delta controls T-cell development, differentiation and regulation.

Systematic identification of SH3 domain-mediated human protein-protein interactions by peptide array target screening.

Huntingtin interacting proteins are genetic modifiers of neurodegeneration.

Interaction with PI3-kinase contributes to the cytotoxic activity of apoptin.

The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations.

Myeloproliferative disorder FOP-FGFR1 fusion kinase recruits phosphoinositide-3 kinase and phospholipase Cgamma at the centrosome.

ICOS ligation recruits the p50alpha PI3K regulatory subunit to the immunological synapse.

TLR4/MyD88/PI3K interactions regulate TLR4 signaling.

Charting the molecular network of the drug target Bcr-Abl.

Mal connects TLR2 to PI3Kinase activation and phagocyte polarization.

A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane.

Identification of SH3 domain interaction partners of human FasL (CD178) by phage display screening.

High content screening for inhibitors of protein interactions and post-translational modifications in primary cells by proximity ligation.

Involvement of Src tyrosine kinase in Escherichia coli invasion of human brain microvascular endothelial cells.

Defining the membrane proteome of NK cells.

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells.

C-mip interacts with the p85 subunit of PI3 kinase and exerts a dual effect on ERK signaling via the recruitment of Dip1 and DAP kinase.

The catalytic PI3K isoforms p110gamma and p110delta contribute to B cell development and maintenance, transformation, and proliferation.

An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells.

A regulatory subunit of phosphoinositide 3-kinase increases the nuclear accumulation of X-box-binding protein-1 to modulate the unfolded protein response.

The emerging mechanisms of isoform-specific PI3K signalling.

NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling.

Abi1/Hssh3bp1 pY213 links Abl kinase signaling to p85 regulatory subunit of PI-3 kinase in regulation of macropinocytosis in LNCaP cells.

Tarp regulates early Chlamydia-induced host cell survival through interactions with the human adaptor protein SHC1.

LAPTM4B: a novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling.

Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.

A human MAP kinase interactome.

Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation.

Phosphoinositide 3-kinase as a novel functional target for the regulation of the insulin signaling pathway by SIRT1.

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer.

Interleukin-18/WNT1-inducible signaling pathway protein-1 signaling mediates human saphenous vein smooth muscle cell proliferation.

Selected reaction monitoring mass spectrometry reveals the dynamics of signaling through the GRB2 adaptor.

Dynamics of the phosphoinositide 3-kinase p110δ interaction with p85α and membranes reveals aspects of regulation distinct from p110α.

NYAP: a phosphoprotein family that links PI3K to WAVE1 signalling in neurons.

Tyrosine phosphorylation of the Gα-interacting protein GIV promotes activation of phosphoinositide 3-kinase during cell migration.

p37δ is a new isoform of PI3K p110δ that increases cell proliferation and is overexpressed in tumors.

Integrin/Fak/Src-mediated regulation of cell survival and anoikis in human intestinal epithelial crypt cells: selective engagement and roles of PI3-K isoform complexes.

NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma.

Viral immune modulators perturb the human molecular network by common and unique strategies.

Activation of rapid oestrogen signalling in aggressive human breast cancers.

FLT3 signals via the adapter protein Grb10 and overexpression of Grb10 leads to aberrant cell proliferation in acute myeloid leukemia.

Development and application of a DNA microarray-based yeast two-hybrid system.

Analysis of protein-protein interactions in cross-talk pathways reveals CRKL protein as a novel prognostic marker in hepatocellular carcinoma.

FBXL2- and PTPL1-mediated degradation of p110-free p85β regulatory subunit controls the PI(3)K signalling cascade.

Insulin receptor substrate-2 is expressed in kidney epithelium and up-regulated in diabetic nephropathy.

Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions.

FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to promote epithelial cell transformation and resistance to targeted therapies.

The interactomes of influenza virus NS1 and NS2 proteins identify new host factors and provide insights for ADAR1 playing a supportive role in virus replication.

Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency.

Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms.

JMJD6 regulates ERα methylation on arginine.

Enhanced prediction of Src homology 2 (SH2) domain binding potentials using a fluorescence polarization-derived c-Met, c-Kit, ErbB, and androgen receptor interactome.

Using an in situ proximity ligation assay to systematically profile endogenous protein-protein interactions in a pathway network.

Hijacking Dlg1 for oncogenic phosphatidylinositol 3-kinase activation in human epithelial cells is a conserved mechanism of human adenovirus E4-ORF1 proteins.

Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors.

A proteome-scale map of the human interactome network.

Phosphorylation of serine 523 on 5-lipoxygenase in human B lymphocytes.

A human interactome in three quantitative dimensions organized by stoichiometries and abundances.

A TRAF-like motif of the inducible costimulator ICOS controls development of germinal center TFH cells via the kinase TBK1.

Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche.

PI3Kδ and primary immunodeficiencies.

Insulin resistance and diabetes caused by genetic or diet-induced KBTBD2 deficiency in mice.

Discovery of 7-(3-(piperazin-1-yl)phenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives as highly potent and selective PI3Kδ inhibitors.

Comparative influenza protein interactomes identify the role of plakophilin 2 in virus restriction.

Transmembrane domain-mediated Lck association underlies bystander and costimulatory ICOS signaling.

Case Study: Mechanism for Increased Follicular Helper T Cell Development in Activated PI3K Delta Syndrome.

Elucidation of protein interactions necessary for the maintenance of the BCR-ABL signaling complex.

PI3K activation is enhanced by FOXM1D binding to p110 and p85 subunits.

Kinase Interaction Network Expands Functional and Disease Roles of Human Kinases.

Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.

A protein interaction landscape of breast cancer.

A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity.

Mapping the Phospho-dependent ALK Interactome to Identify Novel Components in ALK Signaling.

OpenCell: Endogenous tagging for the cartography of human cellular organization.

Physical and functional interactome atlas of human receptor tyrosine kinases.

Systematic discovery of mutation-directed neo-protein-protein interactions in cancer.

Multi-layered proteomics identifies insulin-induced upregulation of the EphA2 receptor via the ERK pathway which is dependent on low IGF1R level.

Gene Ontology annotation through association of InterPro records with GO terms

Manual transfer of experimentally-verified manual GO annotation data to orthologs by curator judgment of sequence similarity

Annotation inferences using phylogenetic trees

Automatic transfer of experimentally verified manual GO annotation data to orthologs using Ensembl Compara

Electronic Gene Ontology annotations created by ARBA machine learning models

Combined automated annotation of GO Cellular Component using UniProtKB/Swiss-Prot Subcellular Location vocabulary mapping

Reactome pathway/reaction R-HSA-109699

Reactome pathway/reaction R-HSA-114542

Reactome pathway/reaction R-HSA-1226012

Reactome pathway/reaction R-HSA-1226014

Reactome pathway/reaction R-HSA-1250189

Reactome pathway/reaction R-HSA-1250346

Reactome pathway/reaction R-HSA-1250353

Reactome pathway/reaction R-HSA-1250370

Reactome pathway/reaction R-HSA-1250462

Reactome pathway/reaction R-HSA-1306957

Reactome pathway/reaction R-HSA-1306965

Reactome pathway/reaction R-HSA-1306979

Reactome pathway/reaction R-HSA-1433514

Reactome pathway/reaction R-HSA-1562641

Reactome pathway/reaction R-HSA-1676048

Reactome pathway/reaction R-HSA-1676109

Reactome pathway/reaction R-HSA-177927

Reactome pathway/reaction R-HSA-177931

Reactome pathway/reaction R-HSA-177939

Reactome pathway/reaction R-HSA-1839078

Reactome pathway/reaction R-HSA-1839080

Reactome pathway/reaction R-HSA-1839091

Reactome pathway/reaction R-HSA-1839102

Reactome pathway/reaction R-HSA-1839107

Reactome pathway/reaction R-HSA-1839114

Reactome pathway/reaction R-HSA-186780

Reactome pathway/reaction R-HSA-186800

Reactome pathway/reaction R-HSA-198266

Reactome pathway/reaction R-HSA-198315

Reactome pathway/reaction R-HSA-201510

Reactome pathway/reaction R-HSA-201515

Reactome pathway/reaction R-HSA-202203

Reactome pathway/reaction R-HSA-202365

Reactome pathway/reaction R-HSA-2029271

Reactome pathway/reaction R-HSA-2029273

Reactome pathway/reaction R-HSA-2045911

Reactome pathway/reaction R-HSA-204798

Reactome pathway/reaction R-HSA-205262

Reactome pathway/reaction R-HSA-2076220

Reactome pathway/reaction R-HSA-2316434

Reactome pathway/reaction R-HSA-2394007

Reactome pathway/reaction R-HSA-2400009

Reactome pathway/reaction R-HSA-2424480

Reactome pathway/reaction R-HSA-2424482

Reactome pathway/reaction R-HSA-2730842

Reactome pathway/reaction R-HSA-2730870

Reactome pathway/reaction R-HSA-388830

Reactome pathway/reaction R-HSA-388832

Reactome pathway/reaction R-HSA-389158

Reactome pathway/reaction R-HSA-416358

Reactome pathway/reaction R-HSA-437118

Reactome pathway/reaction R-HSA-437162

Reactome pathway/reaction R-HSA-443402

Reactome pathway/reaction R-HSA-508247

Reactome pathway/reaction R-HSA-5218819

Reactome pathway/reaction R-HSA-5357479

Reactome pathway/reaction R-HSA-5637765

Reactome pathway/reaction R-HSA-5637801

Reactome pathway/reaction R-HSA-5654591

Reactome pathway/reaction R-HSA-5654592

Reactome pathway/reaction R-HSA-5654594

Reactome pathway/reaction R-HSA-5654596

Reactome pathway/reaction R-HSA-5654612

Reactome pathway/reaction R-HSA-5654614

Reactome pathway/reaction R-HSA-5654620

Reactome pathway/reaction R-HSA-5654622

Reactome pathway/reaction R-HSA-5654637

Reactome pathway/reaction R-HSA-5654640

Reactome pathway/reaction R-HSA-5654641

Reactome pathway/reaction R-HSA-5654643

Reactome pathway/reaction R-HSA-5654659

Reactome pathway/reaction R-HSA-5654662

Reactome pathway/reaction R-HSA-5654667

Reactome pathway/reaction R-HSA-5654669

Reactome pathway/reaction R-HSA-5654690

Reactome pathway/reaction R-HSA-5654692

Reactome pathway/reaction R-HSA-5654697

Reactome pathway/reaction R-HSA-5654701

Reactome pathway/reaction R-HSA-5654705

Reactome pathway/reaction R-HSA-5654709

Reactome pathway/reaction R-HSA-5654714

Reactome pathway/reaction R-HSA-5654717

Reactome pathway/reaction R-HSA-5655235

Reactome pathway/reaction R-HSA-5655240

Reactome pathway/reaction R-HSA-5655245

Reactome pathway/reaction R-HSA-5655248

Reactome pathway/reaction R-HSA-5655252

Reactome pathway/reaction R-HSA-5655263

Reactome pathway/reaction R-HSA-5655285

Reactome pathway/reaction R-HSA-5655289

Reactome pathway/reaction R-HSA-5655290

Reactome pathway/reaction R-HSA-5655315

Reactome pathway/reaction R-HSA-5655320

Reactome pathway/reaction R-HSA-5655323

Reactome pathway/reaction R-HSA-6790041

Reactome pathway/reaction R-HSA-74737

Reactome pathway/reaction R-HSA-879917

Reactome pathway/reaction R-HSA-8851954

Reactome pathway/reaction R-HSA-8852019

Reactome pathway/reaction R-HSA-8854905

Reactome pathway/reaction R-HSA-9012657

Reactome pathway/reaction R-HSA-9013145

Reactome pathway/reaction R-HSA-9014294

Reactome pathway/reaction R-HSA-9018766

Reactome pathway/reaction R-HSA-9021627

Reactome pathway/reaction R-HSA-9021660

Reactome pathway/reaction R-HSA-9027275

Reactome pathway/reaction R-HSA-912627

Reactome pathway/reaction R-HSA-914182

Reactome pathway/reaction R-HSA-9606887

Reactome pathway/reaction R-HSA-9632412

Reactome pathway/reaction R-HSA-9658253

Reactome pathway/reaction R-HSA-9664646

Reactome pathway/reaction R-HSA-9664664

Reactome pathway/reaction R-HSA-9664933

Reactome pathway/reaction R-HSA-9664940

Reactome pathway/reaction R-HSA-9665407

Reactome pathway/reaction R-HSA-9665415

Reactome pathway/reaction R-HSA-9670431

Reactome pathway/reaction R-HSA-9670433

Reactome pathway/reaction R-HSA-9672162

Reactome pathway/reaction R-HSA-9672172

Reactome pathway/reaction R-HSA-9672177

Reactome pathway/reaction R-HSA-9672178

Reactome pathway/reaction R-HSA-9698170

Reactome pathway/reaction R-HSA-9698174

Reactome pathway/reaction R-HSA-9703434

Reactome pathway/reaction R-HSA-9706340

Reactome pathway/reaction R-HSA-9706345

Reactome pathway/reaction R-HSA-9712078

Reactome pathway/reaction R-HSA-9712083

Reactome pathway/reaction R-HSA-9712084

Reactome pathway/reaction R-HSA-9842649

Reactome pathway/reaction R-HSA-9845032

Deep research report on PIK3R1/p85α (Falcon/Edison), synthesized literature review